Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Urologix hopes for much needed revenue boost with Medtronic's Prostiva

This article was originally published in Clinica

Executive Summary

Urologix has gained exclusive worldwide distribution rights to Medtronic's Prostiva radiofrequency ablation device for the treatment of benign prostatic hyperplasia (BPH). The deal makes Urologix the leading provider of doctors' office-based treatments for obstructive urinary conditions caused by BPH – it already markets its own minimally-invasive treatment, Cooled ThermoTherapy (CTT).






Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Add a personalized Question to your Analyst